It doesn't have to. It is a modus operandi to make money for agile fund managers. Forced margins and shaking the tree. Fund wins both ways. Retail gets the shaft.
How can I not like a guy who writes so eloquently and has a vocabulary. BCRX is the proverbial Phoenix, speaking of resurrection. The 10Q points to it(CSL)...nice company along with Shionogi. I can't picture you being such a pessimist. Too many good things have come out of the BCRX think tank and they have formed some quality alliances and locked up distribution.
The punishment doesn't fit the crime. I believe there are other forces at work. We'll see. I've waited a while and I have the time to wait till I'm dead...hopefully before then.
Sandie: Way back when you were in youth hockey Stoney blew up a trial on a compound known as Fodosine... he described the trial results as "interesting"... I screamed and yelled to stop the clock on that placebo and see if he could get a couple grand from MundiPharma for it... well it took awhile but he did give it away... so that little tidbit provides a segue into Stoney's latest blow up... BCRX has/had two compounds for HAE... one has just been renamed Analstat and the other is 7353 which has been shown to be nicely effective... let's hope the man doesn't shoot himself and everyone else in the buttocks by pouring more money into a known loser but somehow wakes up as a CEO and throws out the bad and concentrates on the new...
"This should never have proceded to phase 2."
Correct cape. The trial results showing 35% reduction just weren't strong enough to put tmoney into this. BCRX is famous for trying to plug long gaps in meaningful development with government programs and faux drug candidates. Gout ring a bell? Huge expectations, money plowed in and then:: nothin'. Just nothing at all. Same here with 4161.
So the introduction of the 4430 program, along with the less than 50% reduction results from 4161 told me to exit. The antiviral programs have no multiple because they have no leverage, as Wood says. Thank goodness you still have the 2nd Gen HAE.
But any more pumping govt. antiviral programs should be met with fierce opposition. Their sum total value is on display right now. The tell here is worth a million$. When you see a clinical stage company going to the govt. development trough, it's because they see a huge hole, and risk in their pipeline development some where down the road. I'm sorry this happened to you guys.
Many including Jeffries ($14 to $2). Well they certainly put weight on a formulation that wasn't going to be advanced. Stoney- monetize 4208, start advancing 4430, pound 7353..work with CSL to push P sales (if possible). The sell off puts no value on any of these.
Are you a trader? Check out “ultimatestockalerts”, Just google em. They only alert listed
companies so no OTC scams. The track record says it all.
The share price is approaching the amount of cash per share. Probably a buying opportunity at these prices. They need to save money and move back to Birmingham!
Go back and look at the 10 Q for the quarterly period ending June 30, 2015. Go to the revenue section...it says it all.